<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349607</url>
  </required_header>
  <id_info>
    <org_study_id>B3291010</org_study_id>
    <secondary_id>2014-004468-39</secondary_id>
    <nct_id>NCT02349607</nct_id>
  </id_info>
  <brief_title>Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints</brief_title>
  <official_title>A Double Blind, Double Dummy, Randomized, Placebo-controlled, 5 Period Cross-over Study To Examine The Effect Of Pf-05089771 Alone And In Combination With Pregabalin On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the activity of PF-05089771 and pregabalin, alone and in combination
      on a panel of evoked pain tests carried out from 0.5 to 10 hours following oral dosing in
      healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thermal pain detection threshold</measure>
    <time_frame>1-10 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ultra-violet light sensitized pain detection threshold</measure>
    <time_frame>1-10 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pressure pain tolerance threshold</measure>
    <time_frame>1-10 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrical pain tolerance threshold</measure>
    <time_frame>1-10 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cold pressor tolerance threshold</measure>
    <time_frame>1-10 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0.5-10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>0.5-10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>0.5-10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain detection threshold</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain area under the visual analogue scale pain curve</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain post test visual analogue scale</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain post-cold pressor pain detection threshold</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain post cold pressor pain tolerance threshold</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain post cold pressor area under the visual analogue scale curve</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrical pain post cold pressor post test visual analogue scale</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conditioned pain modulation response pain detection threshold</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conditioned pain modulation pain tolerance threshold</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conditioned pain modulation area under the visual analogue scale curve</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Condition pain modulation post test VAS</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain detection threshold</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain area under the visual analogue scale curve</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain post test visual analogue scale</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold pressor pain detection threshold</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold pressor area under the visual analogue scale curve</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cold pressor post test visual analogue scale</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PF-05089771 half life</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregabalin half life</measure>
    <time_frame>0.5-10 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PF-05089771 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-05089771 300 mg + pregabalin 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pregabalin 300 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen 600 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05089771 300mg</intervention_name>
    <description>PF-05089771 300 mg</description>
    <arm_group_label>PF-05089771 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05089771 300 mg + pregabalin 300 mg</intervention_name>
    <description>PF-05089771 300 mg + pregabalin 300 mg</description>
    <arm_group_label>PF-05089771 300 mg + pregabalin 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placeco</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pregabalin 300 mg</intervention_name>
    <description>pregabalin 300 mg</description>
    <arm_group_label>pregabalin 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibuprofen 600 mg</intervention_name>
    <description>ibuprofen 600 mg</description>
    <arm_group_label>ibuprofen 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects between the ages of 18 and 55 years, inclusive. Healthy is
             defined as no clinically relevant abnormalities identified by a detailed medical
             history, full physical examination, including blood pressure and pulse rate
             measurement, 12 lead ECG or clinical laboratory tests. •Body Mass Index (BMI) of 17.5
             to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). •Evidence of a personally
             signed and dated informed consent document indicating that the subject has been
             informed of all pertinent aspects of the study. •Subjects who are willing and able to
             comply with all scheduled visits, treatment plan, laboratory tests, and other study
             procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at the time of dosing). •Any condition possibly affecting drug
             absorption (eg, gastrectomy). •A positive urine drug screen
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <state>CL</state>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2015</study_first_submitted>
  <study_first_submitted_qc>January 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2015</study_first_posted>
  <last_update_submitted>April 22, 2015</last_update_submitted>
  <last_update_submitted_qc>April 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

